Related Experiment Video

Updated: Jun 7, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development

Massimo Di Maio1, Alessandro Morabito, Maria Carmela Piccirillo

  • 1National Cancer Institute, Clinical Trials Unit, Via Mariano Semmola, 80131 Naples, Italy. dimaiomax@libero.it

Expert Opinion on Investigational Drugs
|November 5, 2010
PubMed
Abstract

Insights

Targeted therapies show promise for non-small-cell lung cancer (NSCLC). Biomarker-driven selection is crucial for achieving significant clinical benefits and improving patient outcomes in NSCLC treatment.

Area of Science:

  • Oncology
  • Translational Medicine
  • Pharmacogenomics

Background:

  • Non-small-cell lung cancer (NSCLC) research is a dynamic field with numerous novel drugs in development.
  • Many investigational drugs for NSCLC feature innovative mechanisms of action.
  • Current clinical practice relies on established treatment modalities for NSCLC.

Purpose of the Study:

  • To review recent clinical findings for promising new drugs in advanced NSCLC.
  • To highlight the importance of biomarker-driven patient selection.
  • To discuss the translation of biological discoveries into clinical applications.

Main Methods:

  • Review of recently published clinical trial results for advanced NSCLC.
  • Analysis of drug efficacy in both unselected and biomarker-selected patient populations.
  • Case study of crizotinib in ALK-rearranged NSCLC.

Main Results:

  • Many new NSCLC drugs are evaluated without biomarker selection due to limited knowledge of predictive factors.
  • A subset of novel agents is tested in NSCLC patients selected based on specific biomarkers.
  • Crizotinib demonstrated rapid clinical translation in ALK-positive NSCLC patients.

Conclusions:

  • NSCLC comprises a spectrum of distinct molecular subtypes, not a single entity.
  • Treatments in unselected populations may offer marginal benefits, failing to significantly alter NSCLC prognosis.
  • Targeted therapies, when used with appropriate biomarker-driven selection, yield superior and cost-effective outcomes in NSCLC.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...